© 2020 MJH Life Sciences and OncLive. All rights reserved.
August 4th 2020
Hatem Soliman, MD, discusses the rationale for using immunotherapy in triple-negative breast cancer.
August 1st 2020
Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.
July 31st 2020
Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.
One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.
Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.
Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.
Hung Khong, MD, discusses antiestrogen and immunotherapy combinations in ER-positive, HER2-negative breast cancer.
July 30th 2020
The FDA has accepted 2 supplemental biologics applications for pembrolizumab in patients with triple-negative breast cancer; these are the first US applications for the anti–PD-1 therapy in breast cancer.
July 29th 2020
The FDA has approved the new VENTANA HER2 Dual ISH DNA Probe Cocktail test for use as a companion diagnostic for trastuzumab and to detect HER2 mutations in patients with breast cancer.
July 21st 2020
Jennifer Litton, MD, discusses findings from the phase 3 EMBRACA trial on talazoparib in patients with advanced BRCA1/2-positive breast cancer.